"Antibiotic Apocalypse Looms: Why the Quest for New Medicines is Failing. The world is on the brink of a public health crisis as antibiotic-resistant bacteria continue to spread, leaving doctors with limited treatment options. Despite the pressing need for new antibiotics, pharmaceutical companies are hesitant to invest in their development due to the daunting costs and uncertain returns. As a result, the pipeline for new antibiotics has dwindled, leaving patients and healthcare systems vulnerable to the growing threat of superbugs. Can the economics of antibiotic development be changed to incentivize innovation and save lives?"
The world urgently needs new antibiotics, yet the market routinely punishes companies that take on the long, risky and expensive work of developing them.
